Our first algorithm that transforms the avalanche of ICU data into actionable information is now on the market. Etiometry has received U.S. Food & Drug (FDA) 510(k) clearance for the first of our Risk Analytics Algorithms. Based on patient-specific data and models of human physiology, these Risk Analytics Algorithms inform physicians and nurses in the intensive care unit (ICU) through our T3 Visualization & Data Aggregation software.
The new Inadequate Oxygen Delivery (IDO2) Index Powered by Risk Analytics for Neonates is the first of many Etiometry algorithms that we are bringing to market. With our IDO2 algorithm, doctors and nurses can quickly assess the risk of inadequate oxygen delivery alongside traditional measures of the patient’s status in a manner that clearly visualizes the patient’s trajectory.
This algorithm is immediately available and can be deployed in the ICU and accessed by critical-care providers using computers or mobile devices secured by the hospital’s network. It allows hospitals to improve the quality of care given to newborn children in ICUs by delivering actionable information through:
- Data consolidation
- Enhanced visualization
Rather than creating isolated algorithms to predict adverse patient outcomes, our innovative technology tracks the patients continuously and comprehensively. By deploying our T3 Visualization & Data Aggregation and Risk Analytics Algorithms, hospitals can leverage our IDO2 Index, which is computed based on multiple physiological measures and laboratory results. This solution allows you to automate data collection and visualize aggregated results on a single screen to better protect the health of critically ill children in the ICU.
For more information, please read the press release and learn more about our Etiometry Platform and our Risk Analytics Algorithms. You can also contact us if you’re interested in deploying this innovative solution in your hospital.